Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2015

01-05-2015 | Brief Report

Acceptability of HIV Pre-exposure Prophylaxis (PrEP) Among People Who Inject Drugs (PWID) in a Canadian Setting

Authors: Daniel J. Escudero, Thomas Kerr, Evan Wood, Paul Nguyen, Mark N. Lurie, Omar Sued, Brandon D. L. Marshall

Published in: AIDS and Behavior | Issue 5/2015

Login to get access

Abstract

A recent clinical trial provided evidence that pre-exposure prophylaxis (PrEP) has the potential to prevent HIV infection among people who inject drugs (PWID). We examined willingness to use PrEP among HIV-negative PWID in Vancouver, Canada (n = 543) to inform PrEP implementation efforts. One third (35.4 %) expressed willingness to use PrEP, with adjusted models indicating that younger age, no regular employment, requiring help injecting, engaging in sex work, and reporting multiple recent sexual partners were positively associated with willingness to use PrEP. Although willingness to use PrEP was low, PrEP was acceptable to some PWID at heightened risk for HIV infection.
Literature
1.
Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.CrossRefPubMedCentralPubMed
2.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRefPubMedCentralPubMed
3.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedCentralPubMed
4.
Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in bangkok, thailand (the bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMed
5.
Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics. PLOS ONE. 2014;9(1):E86584.CrossRefPubMedCentralPubMed
6.
Baral SD, Stromdahl S, Beyrer C. The potential uses of preexposure prophylaxis for HIV prevention among people who inject drugs. Curr Opin HIV AIDS. 2012;7(6):563–8.CrossRefPubMed
7.
Campbell JD, Herbst JH, Koppenhaver RT, Smith DK. Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV. Am J Prev Med. 2013;44(1 Suppl 2):S63–9.CrossRefPubMed
8.
Crawford ND, Vlahov D. Progress in HIV reduction and prevention among injection and noninjection drug users. J Acquir Immune Defic Syndr. 2010;55(Suppl 2):S84–7.CrossRefPubMedCentralPubMed
9.
Dutta MJ. Disseminating HIV pre-exposure prophylaxis information in underserved communities. Am J Prev Med. 2013;44(1 Suppl 2):S133–6.CrossRefPubMed
10.
Escudero DJ, Lurie MN, Kerr T, Howe CJ, Marshall BD. HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research. J Int AIDS Soc. 2014;17:18899.CrossRefPubMedCentralPubMed
11.
Eisingerich AB, Wheelock A, Gomez GB, Garnett GP, Dybul MR, Piot PK. Attitudes and acceptance of oral and parenteral HIV preexposure prophylaxis among potential user groups: a multinational study. PLOS One. 2012;7(1):E28238.CrossRefPubMedCentralPubMed
12.
Stein M, Thurmond P, Bailey G. Willingness to use HIV pre-exposure prophylaxis among opiate users. AIDS Behav. 2014.
13.
Buxton J. Vancouver Site Report for the Canadian Community Epidemiology Network on Drug Use (CCENDU). 2003.
14.
Kerr T, Small W, Buchner C, Zhang R, Li K, Montaner J, et al. Syringe sharing and HIV incidence among injection drug users and increased access to sterile syringes. Am J Public Health. 2010;100(8):1449–53.CrossRefPubMedCentralPubMed
15.
Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532–9.CrossRefPubMedCentralPubMed
16.
Wood E, Kerr T, Marshall BD, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ. 2009;338:b1649.CrossRefPubMedCentralPubMed
17.
18.
U.S. Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2014: a clinical practice guideline. Centers for disease control and prevention, 2014.
19.
20.
Gu J, Bai Y, Lau JT, Hao Y, Cheng Y, Zhou R, et al. Social environmental factors and condom use among female injection drug users who are sex workers in China. AIDS Behav. 2013.
21.
Khan AA, Khan A. Performance and coverage of HIV interventions for injection drug users: insights from triangulation of programme, field and surveillance data from Pakistan. Int J Drug Policy. 2011;22(3):219–25.CrossRefPubMed
22.
Hayashi K, Suwannawong P, Ti L, Kaplan K, Wood E, Kerr T. High rates of midazolam injection and associated harms in Bangkok, Thailand. Addiction. 2013;108(5):944–52.CrossRefPubMed
23.
Kerr T, Marshall BD, Milloy MJ, Zhang R, Guillemi S, Montaner JS, et al. Patterns of heroin and cocaine injection and plasma HIV-1 RNA suppression among a long-term cohort of injection drug users. Drug Alcohol Depend. 2012;124(1–2):108–12.CrossRefPubMedCentralPubMed
24.
Fairbairn N, Small W, Van Borek N, Wood E, Kerr T. Social structural factors that shape assisted injecting practices among injection drug users in Vancouver, Canada: a qualitative study. Harm Reduct J. 2010;7:20.CrossRefPubMedCentralPubMed
25.
Richardson LA, Milloy MJ, Kerr TH, Parashar S, Montaner JS, Wood E. Employment predicts decreased mortality among HIV-seropositive illicit drug users in a setting of universal HIV care. J Epidemiol Community Health. 2014;68(1):93–6.CrossRefPubMedCentralPubMed
26.
Goldenberg SM, Chettiar J, Simo A, Silverman JG, Strathdee SA, Montaner JS, et al. Early sex work initiation independently elevates odds of HIV infection and police arrest among adult sex workers in a Canadian setting. J Acquir Immune Defic Syndr. 2014;65(1):122–8.CrossRefPubMedCentralPubMed
27.
Arnold EA, Hazelton P, Lane T, Christopoulos KA, Galindo GR, Steward WT, et al. A qualitative study of provider thoughts on implementing pre-exposure prophylaxis (prep) in clinical settings to prevent HIV infection. PLOS One. 2012;7(7):E40603.CrossRefPubMedCentralPubMed
28.
Galai N, Safaeian M, Vlahov D, Bolotin A, Celentano DD, Study A. Longitudinal patterns of drug injection behavior in the ALIVE Study cohort 1988–2000: description and determinants. Am J Epidemiol. 2003;158(7):695–704.CrossRefPubMed
Metadata
Title
Acceptability of HIV Pre-exposure Prophylaxis (PrEP) Among People Who Inject Drugs (PWID) in a Canadian Setting
Authors
Daniel J. Escudero
Thomas Kerr
Evan Wood
Paul Nguyen
Mark N. Lurie
Omar Sued
Brandon D. L. Marshall
Publication date
01-05-2015
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2015
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-014-0867-z

Other articles of this Issue 5/2015

AIDS and Behavior 5/2015 Go to the issue

Original Paper

Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya

Original Paper

Understanding Concerns About Treatment-as-Prevention Among People with HIV who are not Using Antiretroviral Therapy

Original Paper

Communication About Microbicide Use Between Couples in KwaZulu-Natal, South Africa

Original Paper

HIV Prevalence and Risk Behaviors Among Female Sex Workers in Botswana: Results from the 2012 HIV/STI Bio-Behavioral Study

Original Paper

Knowledge is Power! Increased Provider Knowledge Scores Regarding Pre-exposure Prophylaxis (PrEP) are Associated with Higher Rates of PrEP Prescription and Future Intent to Prescribe PrEP

Original Paper

Profiles of Risk Among HIV-Infected Youth in Clinic Settings
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits